Seawolf Therapeutics discloses Series A as it emerges from stealth
The company reported $100m across seed and Series A financing without disclosing the amount of either round.
Seawolf Therapeutics disclosed Series A financing on 16 November 2026, backed by Versant Ventures, MPM BioImpact, Novartis Venture Fund and other investors. Its $100 million funding total includes an earlier seed round; the individual allocations were not disclosed. The company will advance DNA medicines using its TRIDENT delivery platform. A separate Sanofi collaboration carries potential milestones of up to $1.2 billion and royalties, rather than investment proceeds.
Use of funds
Advance DNA-delivery therapeutics using TRIDENT
Develop a lead metabolic-disease program